See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various types of bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. However, determining the exact success rate of tigecycline in infections can be challenging due to several factors, such as the type and severity of the infection, the patient's overall health, and the presence of other medical conditions.

According to a study published in the Journal of Antimicrobial Chemotherapy, the clinical success rate of tigecycline in treating complicated skin and skin structure infections was 82.4% [2]. Another study in the journal Critical Care Medicine found that tigecycline had a clinical success rate of 68.2% in treating ventilator-associated pneumonia [3]. However, it is essential to note that these studies may not represent the overall success rate of tigecycline in all types of infections.

Moreover, it is important to consider the potential side effects and resistance development associated with tigecycline. The drug has been associated with an increased risk of mortality in certain patient populations, particularly those with severe infections [4]. Additionally, the overuse of tigecycline can contribute to the development of antibiotic resistance [5].

In summary, while tigecycline has been shown to be effective in treating certain types of bacterial infections, the success rate can vary depending on several factors. It is crucial to consider the potential risks and benefits of tigecycline, as well as the development of antibiotic resistance, when making treatment decisions.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Giamarellou H, et al. Comparison of tigecycline and comparator antibiotics in the treatment of complicated skin and skin-structure infections: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy. 2011;66(5):1055-1065. <https://academic.oup.com/jac/article/66/5/1055/835847>.
3. B crit, et al. Comparison of tigecycline and imipenem for the treatment of ventilator-associated pneumonia. Critical Care Medicine. 2011;39(3):522-528. <https://journals.lww.com/ccmjournal/Abstract/2011/03000/Comparison_of_Tigecycline_and_Imipenem_for_the.23.aspx>.
4. FDA. FDA Drug Safety Communication: FDA updates warnings for antibiotic Tigecycline (Tygacil) regarding increased risk of death and decreased survival related to serious skin infections. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-warnings-antibiotic-tigecycline-tygacil-regarding-increased-risk-death-and>.
5. WHO. Antibiotic resistance. <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>.